

**Supplementary Table 6.** At 6-, 12-, 18-, and 24-Month Persistence of Second Line Treatment in Patients with Crohn's Disease or Ulcerative Colitis

| Index treatment    | 6 mo persistence with<br>≥ 6 mo continuous<br>observation |       | 12 mo persistence with<br>≥ 12 mo continuous<br>observation |       | 18 mo persistence with<br>≥ 18 mo continuous<br>observation |       | 24 mo persistence with<br>≥ 24 mo continuous<br>observation |       |
|--------------------|---|-------|---|-------|---|-------|---|-------|
|                    | No. (%)   | Total | No. (%)   | Total | No. (%)   | Total | No. (%)   | Total |
| Crohn's disease    |   |       |   |       |   |       |   |       |
| Adalimumab         | 40 (87.0)   | 46    | 30 (76.9)   | 39    | 21 (70.0)   | 30    | 15 (60.0)   | 25    |
| Infliximab         | 52 (92.9)   | 56    | 43 (87.8)   | 49    | 38 (86.4)   | 44    | 34 (85.0)   | 40    |
| Vedolizumab        | 9 (100.0)   | 9     | 5 (83.3)  | 6     | 2 (50.0)  | 4     | 2 (50.0)  | 4     |
| Ustekinumab        | 95 (95.0)   | 100   | 74 (91.4)   | 81    | 52 (85.2)   | 61    | 41 (85.4)   | 48    |
| Total              | 196 (92.9)  | 211   | 152 (86.9)  | 175   | 113 (81.3)  | 139   | 92 (78.6)   | 117   |
| Ulcerative colitis |   |       |   |       |   |       |   |       |
| Adalimumab         | 45 (58.4)   | 77    | 30 (50.8)   | 59    | 24 (43.6)   | 55    | 18 (37.5)   | 48    |
| Infliximab         | 71 (60.2)   | 118   | 51 (49.5)   | 103   | 38 (43.7)   | 87    | 27 (37.0)   | 73    |
| Golimumab          | 71 (69.6)   | 102   | 51 (53.1)   | 96    | 32 (39.5)   | 81    | 18 (26.5)   | 68    |
| Vedolizumab        | 94 (83.9)   | 112   | 67 (67.7)   | 99    | 46 (59.7)   | 77    | 35 (56.5)   | 62    |
| Ustekinumab        | 94 (88.7)   | 106   | 62 (76.5)   | 81    | 29 (69.0)   | 42    | 14 (82.4)   | 17    |
| Tofacitinib        | 57 (58.8)   | 97    | 48 (55.8)   | 86    | 35 (55.6)   | 63    | 27 (54.0)   | 50    |
| Total              | 432 (70.6)  | 612   | 309 (59.0)  | 524   | 204 (50.4)  | 405   | 139 (43.7)  | 318   |